WB, IP, IHC-Bond, IHC-P, IF-IC
H
Endogenous
190
Rabbit IgG
#Q9HCU0
57124
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
| IHC Leica Bond | 1:100 - 1:400 |
| Immunohistochemistry (Paraffin) | 1:100 - 1:400 |
| Immunofluorescence (Immunocytochemistry) | 1:200 - 1:400 |
Storage
For a carrier free (BSA and azide free) version of this product see product #68864.
Specificity / Sensitivity
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro403 of human CD248 protein.
Background
CD248, also known as Endosialin and TEM1, is a stromal cell marker expressed on activated mesenchymal cells including fibroblasts and pericytes. Not normally detectable in most adult tissues, it is highly expressed in lymphoid tissues during development, and in disease states where increased stromal cell proliferation and migration are evident (1-3). CD248 is known to be upregulated in breast cancer, brain tumors (4-6), and other malignancies including sarcoma (12), and it has been implicated in sprouting angiogenesis and vasculogenesis (7). It is thought that the CD248 gene is upregulated in response to hypoxic conditions in the tumor environment through HIF2 activation (8). Interestingly, CD248 is found to be highly expressed in activated fibroblasts. In liver fibrosis for example, CD248 marks the Hepatic Stellate Cells, the activated cells responsible for matrix production (9,10). In kidney fibrosis, CD248 marks the key effector cells within the fibrotic stroma including pericytes, myofibroblasts, and stromal fibroblasts (11), and in Idiopathic Pulmonary Fibrosis, CD248 may be a marker for severity of disease (12). CD248 has become a target of interest for pharmaceutical intervention in a wide scope of diseases (13).
- Lax, S. et al. (2010) Eur J Immunol 40, 1884-9.
- Lax, S. et al. (2007) FEBS Lett 581, 3550-6.
- Dolznig, H. et al. (2005) Cancer Immun 5, 10.
- Viski, C. et al. (2016) Cancer Res 76, 5313-25.
- Simonavicius, N. et al. (2008) Mod Pathol 21, 308-15.
- Carson-Walter, E.B. et al. (2009) BMC Cancer 9, 417.
- Kontsekova, S. et al. (2016) Neoplasma 63, 183-92.
- Ohradanova, A. et al. (2008) Br J Cancer 99, 1348-56.
- Wilhelm, A. et al. (2016) Gut 65, 1175-85.
- Mogler, C. et al. (2015) EMBO Mol Med 7, 332-8.
- Smith, S.W. et al. (2011) Kidney Int 80, 199-207.
- Bartis, D. et al. (2016) BMC Pulm Med 16, 51.
- Teicher, B.A. (2019) Oncotarget 10, 993-1009.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v nonfat dry milk, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation IHC-Bond: IHC Leica Bond IHC-P: Immunohistochemistry (Paraffin) IF-IC: Immunofluorescence (Immunocytochemistry)
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.
